A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine whether the combination of low dose cisplatin and
strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in
hormone refractory prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Alberta Health Services
Collaborators:
Amersham Health The Prostate Cancer Research Foundation of Canada